From the Editor

Delayed or on schedule, MACRA is on its way


 

As 2016 winds down, we are already gearing up for the 2019 implementation of the Medicare Access and CHIP Reauthorization Act, or MACRA. The bipartisan 2015 legislation will replace the current sustainable growth rate as well as streamline the existing quality reporting programs and redirect us from the current volume-based Medicare payments to value- and performance-based payments. On page 394 of this issue, two community- based colleagues, JCSO Editor Dr Linda Bosserman and Dr Robin Zon, a community oncologist and chair of the American Society of Clinical Oncology’s Task Force on Clinical Pathways, discuss the ins and outs of MACRA – what it is, what it replaces, how it will work, and what we need to be doing to prepare for its implementation in 2019.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

New anticancer drugs linked to increased costs, life expectancy
MDedge Hematology and Oncology
Getting prior lab results is worth the effort
MDedge Hematology and Oncology
Veterans’ keratinocyte carcinoma, actinic keratosis care cost $356 million in 2012
MDedge Hematology and Oncology
Health sector claims 4 spots among top 10 lobbyers in 2016
MDedge Hematology and Oncology
VIDEO: Medical apps will disrupt health care in a good way
MDedge Hematology and Oncology
EHR woes will get worse before they get better: ONC chief
MDedge Hematology and Oncology
Recommendations for Cancer Moonshot overlook a few issues, YSC says
MDedge Hematology and Oncology
Legislators: Investigate Medicare fraud before paying doctors
MDedge Hematology and Oncology
VIDEO: When is it time to jump into MACRA with both feet?
MDedge Hematology and Oncology
Feds require more transparent reporting of clinical trial results
MDedge Hematology and Oncology